Advertisement

Journal of Cancer Research and Clinical Oncology

, Volume 144, Issue 8, pp 1523–1530 | Cite as

Vaginal brachytherapy for endometrial cancer

  • Peter Hass
  • Selvi Seinsch
  • Holm Eggemann
  • Tanja Ignatov
  • Stephan Seitz
  • Atanas Ignatov
Original Article – Clinical Oncology

Abstract

Background

There is limited information about survival effect of vaginal brachytherapy (VBT) and its comparison to external beam pelvic radiotherapy (EBRT) and no radiotherapy (no-RT) of endometrial cancer patients.

Patients and methods

We performed a multicenter retrospective registry study of 1550 patients with endometrial cancer treated by no-RT (n = 702), VBT (n = 430) and EBRT ± VBT (n = 418). The outcome measure was overall survival.

Results

RT did not improve the overall survival of patients with a low risk of recurrence. In univariate analysis, the survival effect of VBT was significant in patients with intermediate and high risk of recurrence (HR 0.42, CI 0.29–0.60, p < 0.0001). EBRT ± VBT demonstrated no survival effect in these groups. Multivariate analysis showed that VBT (HR 0.50, CI 0.36–0.71) significantly reduced the mortality risk in patients with an intermediate and high risk compared with no-RT after adjustment for age, tumor grading, tumor stage, lymphadenectomy, adjuvant therapy and comorbidities. Matching for age, histological type, tumor stage, tumor grade, and performance status between patients treated with no-RT and VBT was performed. The matching analysis again demonstrated the favorable survival effect of VBT compared to no-RT on overall survival with an absolute risk reduction of 17.7%. Notably, in a further 106 matched pairs, EBRT ± VBT did not demonstrate any survival effect over VBT among patients at intermediate and high risk of recurrence.

Conclusions

VBT should be performed in patients at intermediate and high risk of recurrence of endometrial cancer, after operative determination of lymph node status.

Keywords

Endometrial cancer VBT EBRT 

Notes

Funding

This study was not funded.

Compliance with ethical standards

Conflict of interest

All authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with animals performed by any of the authors. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Written informed consent was obtained from all patients before treatment. According to the statement of Research and Ethical Committee, Otto-von-Guericke University, Magdeburg, Germany, an additional individual consent was not required for this analysis. Before analysis, patient data underwent a pesudonymisation.

References

  1. Aalders J, Abeler V, Kolstad P, Onsrud M (1980) Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. Obstet Gynecol 56:419–427PubMedGoogle Scholar
  2. Anderson JM, Stea B, Hallum AV, Rogoff E, Childers J (2000) High-dose-rate postoperative vaginal cuff irradiation alone for stage IB and IC endometrial cancer. Int J Radiat Oncol Biol Phys 46:417–425CrossRefPubMedGoogle Scholar
  3. Battista MJ, Steiner E, Rieks N, Steetskamp J, Seeger A, Sicking I et al (2013) Nationwide analysis on surgical staging procedures and systemic treatment for patients with endometrial cancer in Germany. Int J Gynecol Cancer 23:105–112CrossRefPubMedGoogle Scholar
  4. Bendifallah S, Canlorbe G, Huguet F, Coutant C, Hudry D, Graesslin O et al (2014) A risk scoring system to determine recurrence in early-stage type 1 endometrial cancer: a French multicentre study. Ann Surg Oncol 21:4239–4245CrossRefPubMedGoogle Scholar
  5. Blake P, Swart AM, Orton J, Kitchener H, Whelan T, Lukka H et al (2009) Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet 373:137–146CrossRefPubMedGoogle Scholar
  6. Chadha M, Nanavati PJ, Liu P, Fanning J, Jacobs A (1999) Patterns of failure in endometrial carcinoma stage IB grade 3 and IC patients treated with postoperative vaginal vault brachytherapy. Gynecol Oncol 75:103–107CrossRefPubMedGoogle Scholar
  7. Chan JK, Kapp DS (2007) Role of complete lymphadenectomy in endometrioid uterine cancer. Lancet Oncol 8:831–841CrossRefPubMedGoogle Scholar
  8. Colombo N, Preti E, Landoni F, Carinelli S, Colombo A, Marini C et al (2011) Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 22(Suppl 6):vi35–vi39Google Scholar
  9. Colombo N, Creutzberg C, Amant F, Bosse T, Gonzalez-Martin A, Ledermann J et al (2016) ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. Ann Oncol 27:16–41CrossRefGoogle Scholar
  10. Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Warlam-Rodenhuis CC et al (2000) Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 355:1404–1411CrossRefPubMedGoogle Scholar
  11. DuBeshter B, Estler K, Altobelli K, McDonald S, Glantz C, Angel C (2004) High-dose rate brachytherapy for Stage I/II papillary serous or clear cell endometrial cancer. Gynecol Oncol 94:383–386CrossRefPubMedGoogle Scholar
  12. Eggemann H, Ignatov T, Kaiser K, Burger E, Costa SD, Ignatov A (2016) Survival advantage of lymphadenectomy in endometrial cancer. J Cancer Res Clin Oncol 142:1051–1060CrossRefPubMedGoogle Scholar
  13. Elshaikh MA, Vance S, Suri JS, Mahan M, Munkarah A (2014) Improved survival endpoints with adjuvant radiation treatment in patients with high-risk early-stage endometrial carcinoma. Int J Radiat Oncol Biol Phys 88:351–356CrossRefPubMedGoogle Scholar
  14. Hogberg T, Signorelli M, de Oliveira CF, Fossati R, Lissoni AA, Sorbe B et al (2010) Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer—results from two randomised studies. Eur J Cancer 46:2422–2431CrossRefPubMedPubMedCentralGoogle Scholar
  15. Keys HM, Roberts JA, Brunetto VL, Zaino RJ, Spirtos NM, Bloss JD et al (2004) A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 92:744–751CrossRefPubMedGoogle Scholar
  16. Kim A, Schreiber D, Rineer J, Choi K, Rotman M (2011) Impact of adjuvant external-beam radiation therapy in early-stage uterine papillary serous and clear cell carcinoma. Int J Radiat Oncol Biol Phys 81:e639–e644Google Scholar
  17. Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK (2009) Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet 373:125–136CrossRefPubMedGoogle Scholar
  18. Macdonald OK, Sause WT, Lee RJ, Lee CM, Dodson MK, Zempolich K et al (2006) Adjuvant radiotherapy and survival outcomes in early-stage endometrial cancer: a multi-institutional analysis of 608 women. Gynecol Oncol 103:661–666CrossRefPubMedGoogle Scholar
  19. Maggi R, Lissoni A, Spina F, Melpignano M, Zola P, Favalli G et al (2006) Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial. Br J Cancer 95:266–271CrossRefPubMedPubMedCentralGoogle Scholar
  20. McCloskey SA, Tchabo NE, Malhotra HK, Odunsi K, Rodabaugh K, Singhal P et al (2010) Adjuvant vaginal brachytherapy alone for high risk localized endometrial cancer as defined by the three major randomized trials of adjuvant pelvic radiation. Gynecol Oncol 116:404–407CrossRefPubMedGoogle Scholar
  21. Nout RA, Putter H, Jurgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, van der Steen-Banasik EM et al (2009) Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial. J Clin Oncol 27:3547–3556CrossRefPubMedGoogle Scholar
  22. Nout RA, Smit VT, Putter H, Jurgenliemk-Schulz IM, Jobsen JJ, Lutgens LC et al (2010) Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet 375:816–823CrossRefPubMedGoogle Scholar
  23. Pecorelli S (2009) Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 105:103–104CrossRefPubMedGoogle Scholar
  24. Randall ME, Filiaci VL, Muss H, Spirtos NM, Mannel RS, Fowler J et al (2006) Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 24:36–44CrossRefPubMedGoogle Scholar
  25. Sorbe B, Nordstrom B, Maenpaa J, Kuhelj J, Kuhelj D, Okkan S et al (2009) Intravaginal brachytherapy in FIGO stage I low-risk endometrial cancer: a controlled randomized study. Int J Gynecol Cancer 19:873–878CrossRefPubMedGoogle Scholar
  26. Sorbe B, Horvath G, Andersson H, Boman K, Lundgren C, Pettersson B (2012) External pelvic and vaginal irradiation versus vaginal irradiation alone as postoperative therapy in medium-risk endometrial carcinoma—a prospective randomized study. Int J Radiat Oncol Biol Phys 82:1249–1255CrossRefPubMedGoogle Scholar
  27. Susumu N, Sagae S, Udagawa Y, Niwa K, Kuramoto H, Satoh S et al (2008) Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecol Oncol 108:226–233CrossRefPubMedGoogle Scholar
  28. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP (2007) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 370:1453–1457CrossRefGoogle Scholar
  29. Weiss E, Hirnle P, Arnold-Bofinger H, Hess CF, Bamberg M (1998) Adjuvant vaginal high-dose-rate afterloading alone in endometrial carcinoma: patterns of relapse and side effects following low-dose therapy. Gynecol Oncol 71:72–76CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Radiation OncologyOtto-von-Guericke UniversityMagdeburgGermany
  2. 2.Department of Obstetrics and GynecologyOtto-von-Guericke UniversityMagdeburgGermany
  3. 3.Department of Gynecology and ObstetricsUniversity Medical Center RegensburgRegensburgGermany

Personalised recommendations